1、nistration 1It is transplanted to the right chest of the anti-tumor effect human gastric cancer strain (OCUM-2MD3) the old 6-week-old male nude rats with intermittent administration schedule in Test Example 7 rat. Measuring the major axis of tumor (mm) and minor axis (mm) after tumor implantation, t
2、he tumor volume: After calculating the (tumor volume TV), allocates the mouse average TV each group to be equal in each group, the the days that are conducted grouped the (n=5) is the day 0. TAS-120 3 mg/kg/day, 30 mg/kg/day, is prepared so as to 100 mg/kg/day, 3 mg/kg/day is daily administered oral
3、ly, 30 mg/kg/day is administered orally every other day, 100 mg/kg/day is performed oral administration of 2 time/week from day 1, provided with the evaluation period of 14 days, the final valuation date it is day 15.MCE has not independently confirmed the accuracy of these methods. They are for ref
4、erence only.REFERENCES1. Hiroaki OCHIIWA, et al. Antitumor drug for intermittent administration of fgfr inhibitor. WO 2015008839 A1.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Pa
5、rk Dr, Suite Q, Monmouth Junction, NJ 08852, USAwww.MedChemE2垜垜则视为该事件不影响施工进度或分包人放弃索赔工期的权利，承包人可拒绝做出任何延期的决定。22、暂停施工和复工发包人或监理工程师认为确有必要暂停施工时，应以书面形式通过承包人向分包人发出暂停施工指令，并在 48 小时内提出处理意见。承包人认为确有必要也可以书面形式向分包人发出暂停施工指令，并在 48 小时内提出处理意见。分包人停工和复工程序以及暂停施工所发生的费用，按总包合同相应条款执行。23、加快进度23.1 在分包人无任何理由取得顺延工期的情况下，如果承包人认为分包工程
6、或其任何部分的进度过慢，与进度计划不符或不能按期竣工，则承包人应书面通知分包人加快进度。分包人应采取必要措施，加快工程进度。如果分包人在接到承包人通知后的 14 天内，未能采取加快工程进度的措施，致使实际工程进度进一步滞后；或分包人虽然采取了一些措施，仍无法按期竣工，承包人可按第 51 条的规定解除合同，也可将分包工程中的一部分工作交由第三方完成。分包人既应承担由此增加的一切费用，也不能免除其根据合同约定应负的任何责任和义务。23.2 如果承包人希望分包人在计划竣工日期之前完成分包工程，应事先征得分包人同意。如果分包人同意，那么承包人可要求分包人提交为加快进度而编制的建议书。分包人应在 7 天
7、内作出书面回应，该建议书的内容至少应包括：（1）加快进度拟采取的措施；（2）加快进度后的进度计划,以及与原计划的对比；（3）加快进度所需的合同价款增加额。该增加额按第 40、54 条规定计算。承包人应在接到建议书后的 7 天内予以答复。如果承包人接受了该建议书，应以书面形式发出变更指令，相应调整工期，并核实和调整合同价款。24、竣工日期24.1 分包人必须按照协议书约定的竣工日期或承包人同意顺延的工期竣工。24.2 实际竣工日期按下列情况分别确定：（1）分包工程经竣工验收合格的，以分包人提请承包人进行竣工验收的日期为实际竣工日期。（2）分包工程竣工验收不合格的，分包人应按要求修改后再次提请承包
8、人验收，以分包人再次提请承包人进行竣工验收的日期为实际竣工日期。（3）分包人已经提交竣工验收报告，承包人在收到分包人送交的竣工验收报告后 14 天内未能组织验收，或验收后 7 天内不提出修改意见的，以分包人提请承包人进行竣工验收日期为实际竣工日期。（4）分包工程未经竣工验收，承包人或发包人擅自使用的，以转移占有分包工程之日为实际竣工日期。24.3 因分包人原因不能按照协议书约定的竣工日期或承包人同意顺延的工期竣工的，分包人承担相应责任。25、误期赔偿25.1 如果分包人未能按照协议书约定的竣工日期或承包人同意顺延的工期竣工，分包人应按第 38 条规定向承包人支付误期赔偿费，但误期赔偿费的支付不
9、能免除分包人根据合同约定应负的任何责任和义务。25.2 误期（实际延误竣工天数）按第 24.2 款规定的实际竣工日期减去协议书约定的竣工日期或承包人同意顺延的日期，即按照下述公式计算：实际延误竣工天数实际竣工日期 协议书约定的竣工日期或承包人同意顺延的日期。上述各相关日期，依据本合同相关条款确定。五、质量和安全26、质量目标、检查与验收26.1 分包工程质量必须达到国家规定的工程质量验收评定标准。总包合同对工程质量另有约定的，分包工程质量也应达到这一标准。26.2 承包人分包人对工程质量有争议的，按第 50.4 款规定调解或认定，或者由双方共同选定的工程质量检测机构鉴定，所需的费用及因而造成的
10、损失，由责任方承担。双方均有责任的，由双方根据其责任划分分别承担。26.3 分包人应建立和保持完善的质量保证体系。在分包工程实施前，承包人有权要求分包人提交质量保证体系实施程序和贯彻质量要求的文件。分包人遵守质量保证体系，也不能免除分包人根据合同约定应负的任何责任和义务。26.4 分包工程质量的检查、验收及工程试车等，按照总包合同相应的条款执行。分包人应就分包工程向承包人承担总包合同约定的承包人应承担的责任和义务，但并不能免除承包人根据总包合同应承担的总包质量管理的责任。26.5 分包人应允许并配合承包人和监理工程师进入分包人施工场地检查工程质量。27、工程照管27.1 从开工之日起，分包人应
11、全面负责照管分包工程及运至现场将用于和安装在分包工程中的材料设备，直到分包工程竣工验收合格之日止。此后，工程的照管即转由承包人负责。 Inhibitors, Agonists, Screening Librarieswww.MedChemESafety Data SheetRevision Date:Oct.-11-2018Print Date: Oct.-11-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name : TAS-120Catalog No. : HY-100818CAS No. :
12、 1448169-71-81.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses : Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany: MedChemExpress USATel: 609-228-6898Fax: 609-228-5909E-mail: 1.4 Emergency telep
13、hone numberEmergency Phone #: 609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON ING
14、REDIENTS3.1 SubstancesSynonyms: NoneFormula: C22H22N6O3Molecular Weight: 418.45CAS No. : 1448169-71-84. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelidswith f
15、ingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.Page 1 of 5 www.MedChemEInhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, gi
16、ve cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see sec
17、tion 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the sub
18、stance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid br
19、eathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnelto safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for
20、containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces andequipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvo
21、id inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaustventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources o
22、f ignition.Recommended storage temperature:Powder-20C 3 years4C 2 yearsIn solvent-80C 6 months-20C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersPage 2 of 5 www.MedChemEComponents with w
23、orkplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shie
24、lds.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controlsKeep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERT
25、IES9.1 Information on basic physical and chemical propertiesAppearance White to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data a
26、vailableFlammability (solid, gas) No data availableUpper/lower flammability or explosive limitsNo data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temp
27、erature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilit
28、yStable under recommended storage conditions.10.3 Possibility of hazardous reactionsPage 3 of 5 www.MedChemENo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire co
29、nditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available d
30、ata. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more d
31、etails, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible orconfirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a pot
32、ential or confirmedcarcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmedcarcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or c
33、onfirmedcarcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on
34、available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility
35、 in soilNo data available.Page 4 of 5 www.MedChemE12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose subst
36、ance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIO
